Early rhythm ‐control ablation therapy to prevent atrial fibrillation recurrences: Insights from the CHARISMA Registry

ConclusionsAn early rhythm-control ablation therapy in the absence of common risk factors was associated with the lowest rate of recurrences.Clinical Trial RegistrationCatheter Ablation of Arrhythmias with a High-Density Mapping System in Real-World Practice (CHARISMA). URL:http://clinicaltrials.gov/ Identifier: NCT03793998.This article is protected by copyright. All rights reserved

Source: Pacing and Clinical Electrophysiology : PACE - October 5, 2021 Category: Cardiology Authors: Francesco Solimene, Mario Giannotti Santoro, Giuseppe Stabile, Maurizio Malacrida, Antonio De Simone, Claudio Pandozi, Gemma Pelargonio, Pietro Rossi, Alberto Battaglia, Domenico Pecora, Maria Grazia Bongiorni, Giulio Zucchelli, Camilla Stocco Tags: ORIGINAL ‐ ELECTROPHYSIOLOGY Source Type: research